Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Standardizing analysis of circulating microRNA: clinical and biological relevance.

Farina NH, Wood ME, Perrapato SD, Francklyn CS, Stein GS, Stein JL, Lian JB.

J Cell Biochem. 2014 May;115(5):805-11. doi: 10.1002/jcb.24745.

2.

Assessing sample and miRNA profile quality in serum and plasma or other biofluids.

Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilum M, Dahlsveen IK.

Methods. 2013 Jan;59(1):S1-6. doi: 10.1016/j.ymeth.2012.09.015. Epub 2012 Oct 2.

3.

U6 is not a suitable endogenous control for the quantification of circulating microRNAs.

Xiang M, Zeng Y, Yang R, Xu H, Chen Z, Zhong J, Xie H, Xu Y, Zeng X.

Biochem Biophys Res Commun. 2014 Nov 7;454(1):210-4. doi: 10.1016/j.bbrc.2014.10.064. Epub 2014 Oct 18.

PMID:
25450382
4.

Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy.

Vigneron N, Meryet-Figuière M, Guttin A, Issartel JP, Lambert B, Briand M, Louis MH, Vernon M, Lebailly P, Lecluse Y, Joly F, Krieger S, Lheureux S, Clarisse B, Leconte A, Gauduchon P, Poulain L, Denoyelle C.

Mol Oncol. 2016 Aug;10(7):981-92. doi: 10.1016/j.molonc.2016.03.005. Epub 2016 Apr 2.

5.

Circulating miRNAs are correlated with tumor progression in prostate cancer.

Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sültmann H.

Int J Cancer. 2011 Feb 1;128(3):608-16. doi: 10.1002/ijc.25376.

6.

Methodological challenges in utilizing miRNAs as circulating biomarkers.

Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M.

J Cell Mol Med. 2014 Mar;18(3):371-90. doi: 10.1111/jcmm.12236. Epub 2014 Feb 18. Review.

7.

Variability in microRNA recovery from plasma: Comparison of five commercial kits.

Brunet-Vega A, Pericay C, Quílez ME, Ramírez-Lázaro MJ, Calvet X, Lario S.

Anal Biochem. 2015 Nov 1;488:28-35. doi: 10.1016/j.ab.2015.07.018. Epub 2015 Aug 10.

PMID:
26271186
8.

Identification of reference microRNAs and suitability of archived hemopoietic samples for robust microRNA expression profiling.

Viprey VF, Corrias MV, Burchill SA.

Anal Biochem. 2012 Feb 15;421(2):566-72. doi: 10.1016/j.ab.2011.10.022. Epub 2011 Oct 18.

PMID:
22074795
9.

Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer.

Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY.

Clin Chem. 2012 Mar;58(3):610-8. doi: 10.1373/clinchem.2011.172767. Epub 2011 Dec 22.

10.

Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis.

Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G.

J Transl Med. 2015 Aug 12;13:261. doi: 10.1186/s12967-015-0623-9.

11.

Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer.

Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, Kantoff PW.

Prostate. 2013 Mar;73(4):346-54. doi: 10.1002/pros.22572. Epub 2012 Aug 10.

12.

Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations.

Williams Z, Ben-Dov IZ, Elias R, Mihailovic A, Brown M, Rosenwaks Z, Tuschl T.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4255-60. doi: 10.1073/pnas.1214046110. Epub 2013 Feb 25.

13.

Clinical evaluation of microRNA expression profiling in non small cell lung cancer.

Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E.

Lung Cancer. 2013 Sep;81(3):388-96. doi: 10.1016/j.lungcan.2013.05.007. Epub 2013 Jun 10.

PMID:
23756108
14.

Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers.

Pescador N, Pérez-Barba M, Ibarra JM, Corbatón A, Martínez-Larrad MT, Serrano-Ríos M.

PLoS One. 2013 Oct 15;8(10):e77251. doi: 10.1371/journal.pone.0077251. eCollection 2013.

15.

Assay reproducibility in clinical studies of plasma miRNA.

Rice J, Roberts H, Burton J, Pan J, States V, Rai SN, Galandiuk S.

PLoS One. 2015 Apr 8;10(4):e0121948. doi: 10.1371/journal.pone.0121948. eCollection 2015.

16.

Method for microRNA isolation from clinical serum samples.

Li Y, Kowdley KV.

Anal Biochem. 2012 Dec 1;431(1):69-75. doi: 10.1016/j.ab.2012.09.007. Epub 2012 Sep 11.

17.

Methods and matrices: approaches to identifying miRNAs for nasopharyngeal carcinoma.

Plieskatt JL, Rinaldi G, Feng Y, Levine PH, Easley S, Martinez E, Hashmi S, Sadeghi N, Brindley PJ, Bethony JM, Mulvenna JP.

J Transl Med. 2014 Jan 6;12:3. doi: 10.1186/1479-5876-12-3.

18.

Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.

Zhang S, Ouyang X, Jiang X, Gu D, Lin Y, Kong SK, Xie W.

Int J Med Sci. 2015 Jul 16;12(7):590-8. doi: 10.7150/ijms.11525. eCollection 2015.

19.

High Throughput qPCR Expression Profiling of Circulating MicroRNAs Reveals Minimal Sex- and Sample Timing-Related Variation in Plasma of Healthy Volunteers.

Mooney C, Raoof R, El-Naggar H, Sanz-Rodriguez A, Jimenez-Mateos EM, Henshall DC.

PLoS One. 2015 Dec 23;10(12):e0145316. doi: 10.1371/journal.pone.0145316. eCollection 2015.

20.

Detection of circulatory microRNAs in prostate cancer.

Srivastava A, Goldberger H, Afzal Z, Suy S, Collins SP, Kumar D.

Methods Mol Biol. 2015;1238:523-38. doi: 10.1007/978-1-4939-1804-1_27.

PMID:
25421678

Supplemental Content

Support Center